ChinaDaily Briefs

Daily Brief China: Shanghai Shenzhen CSI 300 Inde, China Traditional Chinese Medicine, New Oriental Education & Techn, Alibaba (ADR), Semiconductor Manufacturing International Corp (SMIC), Meituan, Shanghai Spacecom Satellite Technology and more

In today’s briefing:

  • China ETF Inflows & Impact: Concentrated, Then Diversified; Central Huijin Steps Up
  • TCM (570 HK): We’ve Been Here Before
  • EDU/TAL:  China Tutoring – Here Comes The Policy Tailwind
  • Alibaba (BABA US): Upzised Share Repurchase to Support Share Price
  • SMIC (981.HK): The GM Reaches a New Low of 9-11% in 1Q24F, Despite Revenue Growing by 2% QoQ.
  • [Meituan (3690 HK, SELL, TP HK$57) Rating Change]: No Quick Skip to the Near-Term Pressures
  • Chinese Startup Raises $943 Million to Fund Race with Starlink


China ETF Inflows & Impact: Concentrated, Then Diversified; Central Huijin Steps Up

By Brian Freitas

  • Nearly US$37bn has flowed into mainland China listed ETFs since 2 January and could be driven by the National Team supporting the market. Central Huijin has announced their ETF buying.
  • Most of the inflows have been focused on large cap indices including CSI 300, SSE50, CSI 500, CSI 1000, ChiNext, STAR50 and Chinext50 indices.
  • While the inflows were initially focused on the CSI 300, there has been a diversification recently with big inflows to the SSE50, CSI 500, CSI 1000 and ChiNext indices.

TCM (570 HK): We’ve Been Here Before

By David Blennerhassett

  • China Traditional Chinese Medicine (570 HK) (“TCM”) is the traditional Chinese medicine arm of SASAC-managed China National Pharmaceutical Group Corporation (CNPGC), one of the largest healthcare groups in China.
  • By my reckoning, TCM has fielded three Offers in the past decade, all from Sinopharm Hongkong, an indirect wholly-owned subsidiary of CNPGC and TCM’s major shareholder.
  • TCM was suspended “pursuant to the Code on Takeovers and Mergers” earlier today. The Real McCoy? A no-deal again from CNPGC/Sinopharm? And why didn’t the last Offers complete?

EDU/TAL:  China Tutoring – Here Comes The Policy Tailwind

By Steve Zhou, CFA

  • Today, after Hong Kong market close, the Ministry of Education issued a new draft regulation on K12 tutoring. 
  • I have written before on New Oriental Education & Techn (EDU US) and China Beststudy that there is now a equilibrium reached between all parties on tutoring in China. 
  • The new draft regulation basically puts it into concrete policy, which should alleviate investor concern on the sector. 

Alibaba (BABA US): Upzised Share Repurchase to Support Share Price

By Eric Chen

  • Alibaba reported a largely in-line December quarter as lower take rate and widened loss from international commerce businesses resulted in pressured bottom line.
  • The results also suggest a persisting pattern of China consumers trading down, which – along with the company’s ongoing internal overhaul – will continue to be headwind in 1H24.
  • That said, we see increase of US$25 billion share repurchase program and dividend policy to well support share price at current valuation. 

SMIC (981.HK): The GM Reaches a New Low of 9-11% in 1Q24F, Despite Revenue Growing by 2% QoQ.

By Patrick Liao

  • The 1Q24F outlook is still showing a decline, with a slightly increase in revenue of 2% QoQ. However, the GM is expected to decrease to 9-11% from 16.4% in 4Q23.
  • Management predicts that there will be a double U-shaped recovery in 2024F. Revenue in 2024F is expected to grow annually by mid-single-digit.
  • The main areas of growth for SMIC in 2024F will be in mobile phones, smart homes, IoT, and computing.

[Meituan (3690 HK, SELL, TP HK$57) Rating Change]: No Quick Skip to the Near-Term Pressures

By Ying Pan

  • We expect Meituan continue under pressure in the medium term due to the intensified competition with Douyin, and Meituan’s low price defending strategy in both food delivery and IHT businesses.
  • Our non-IFRS net profit is roughly in-line with consensus in 4Q23 but 20%/25% lower than consensus in 2024/25.
  • We downgrade the stock to SELL rating and cut TP to HK$57/share.

Chinese Startup Raises $943 Million to Fund Race with Starlink

By Caixin Global

  • Shanghai Spacecom Satellite Technology, a space tech startup backed by the Shanghai municipal government, has raised 6.7 billion yuan ($943 million) to fund the construction of a low-orbit satellite constellation that will provide broadband access to the internet
  • The Series A funding round was led by Shanghai Alliance Investment Ltd., an investment fund backed by the Shanghai government and a founding investor of Spacecom.
  • Other investors include CAS Investment Management Co. Ltd., Hengxu Capital, Guotai Junan Securities Co. Ltd. and CAS Star.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars